Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity.
Lydia G StoneMichael E GrintonJames Stephen TalksPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2021)
The RCOphth guidance to prioritise intravitreal injections for nAMD over DMO appears appropriate in this cohort but not for RVO. Eyes with nAMD experienced the greatest loss of vision with treatment delay, and nAMD and RVO eyes were less likely to return to baseline on restarting treatment.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- optical coherence tomography
- sars cov
- ejection fraction
- healthcare
- coronavirus disease
- newly diagnosed
- rheumatoid arthritis patients
- diabetic retinopathy
- ankylosing spondylitis
- combination therapy
- vascular endothelial growth factor
- respiratory syndrome coronavirus
- patient reported